Joseph Mace, MD
Medical Oncology · St Petersburg, FLNPI 1083605240
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.3%), consulting fees and other — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Spectrum Pharmaceuticals Inc. at 38.6% of the total. Reporting peaked in 2019 at $9,469 and has fallen 67.2% since, to $3,106 in 2025.
Across 576 payments — averaging $35.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Spectrum Pharmaceuticals Inc.$8K
- Novartis$2K
- Daiichi Sankyo Inc.$835
- Gilead$731
- E.r. Squibb & Sons, L.L.C.$707
- Pfizer$671
- plus $8K from 54 others
Across 292 payments — averaging $2684.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$328K
- Janssen Research & Development, LLC$305K
- AstraZeneca$56K
- Genentech, Inc.$41K
- Bristol Myers Squibb$33K
- Pfizer$20K
- plus $928 from 1 others
What the payments were for
- Consulting fees$7,87539%
- Food & beverage$11,90758%
- Education$470%
- Other$5983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$111
How this compares
$20,427 in reported general payments places this provider in the 70th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 19 | $267,106 |
| LumakrasSotorasib | 12 | $253,658 |
| BrukinsaZanubrutinib | 21 | $230,537 |
| ImbruvicaIbrutinib | 13 | $212,751 |
| LynparzaOlaparib | 12 | $202,483 |
| EliquisApixaban | 103 | $90,433 |
| Abiraterone Acetate | 15 | $33,750 |
| XareltoRivaroxaban | 18 | $21,403 |
| Exemestane | 31 | $3,702 |
| Anastrozole | 160 | $3,251 |
| Letrozole | 90 | $2,331 |
| Morphine Sulfate ErMorphine Sulfate | 95 | $2,257 |
| Prochlorperazine Maleate | 53 | $1,620 |
| Ondansetron OdtOndansetron | 34 | $1,310 |
| Oxycodone Hcl | 76 | $1,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $286 | $267,10619 claims |
| AmgenLumakras | $218 | $253,65812 claims |
| Beigene USA, Inc.Brukinsa | $41 | $230,53721 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $44 | $212,75113 claims |
| AstraZenecaLynparza | $441 | $202,48312 claims |
| PfizerEliquis | $671 | $90,433103 claims |
| Johnson & JohnsonXarelto | $515 | $21,40318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 medical oncology providers in Florida.
Other medical oncology in St Petersburg
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.